KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other financing activities (2016 - 2025)

Eli Lilly's Other financing activities history spans 15 years, with the latest figure at -$25.1 million for Q4 2025.

  • For Q4 2025, Other financing activities rose 45.32% year-over-year to -$25.1 million; the TTM value through Dec 2025 reached -$772.0 million, down 57.23%, while the annual FY2025 figure was -$772.0 million, 57.23% down from the prior year.
  • Other financing activities reached -$25.1 million in Q4 2025 per LLY's latest filing, up from -$30.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of -$500000.0 in Q3 2021 to a low of -$686.3 million in Q1 2025.
  • Average Other financing activities over 5 years is -$110.1 million, with a median of -$27.6 million recorded in 2025.
  • Peak YoY movement for Other financing activities: surged 98.55% in 2021, then tumbled 2183.33% in 2022.
  • A 5-year view of Other financing activities shows it stood at -$600000.0 in 2021, then crashed by 2183.33% to -$13.7 million in 2022, then plummeted by 130.66% to -$31.6 million in 2023, then crashed by 45.25% to -$45.9 million in 2024, then surged by 45.32% to -$25.1 million in 2025.
  • Per Business Quant, the three most recent readings for LLY's Other financing activities are -$25.1 million (Q4 2025), -$30.2 million (Q3 2025), and -$30.4 million (Q2 2025).